Newly-born Candid wastes no time in entering M&A market

10 September 2024

Candid Therapeutics, a San Diego biotech focused on developing potentially transformative drugs to address autoimmune diseases, has announced its official launch.

In the same announcement, the company announced that it was acquiring fellow biotechs Vignette Bio and TRC 2004 through a simultaneous three-way merger and multi-step financing.

Explaining the reasons for its confidence in its approach, Candid cited recent ground-breaking clinical data that has showcased the pivotal role of a specific subset of immune cells, B lymphocytes, in autoimmune diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK